Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Nov 18, 2014; 5(5): 653-659
Published online Nov 18, 2014. doi: 10.5312/wjo.v5.i5.653
Inhibition of rheumatoid arthritis by blocking connective tissue growth factor
Kazuhisa Nozawa, Maki Fujishiro, Yoshinari Takasaki, Iwao Sekigawa
Kazuhisa Nozawa, Yoshinari Takasaki, Department of Rheumatology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Maki Fujishiro, Iwao Sekigawa, Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba 261-7114, Japan
Iwao Sekigawa, Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba 261-7114, Japan
Author contributions: All authors contributed to this paper.
Supported by Grant-in-Aid for Scientific Research (C), The Ministry of Education, Culuture, Sports, Science and Technology and The Institute for Environment and Gender-specific Medicine, Juntendo University Graduate School of Medicine
Correspondence to: Kazuhisa Nozawa, MD, PhD, Department of Rheumatology, School of Medicine, Juntendo University 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Telephone: +81-3-58021067 Fax: +81-3-58004893
Received: December 26, 2013
Revised: April 14, 2014
Accepted: July 17, 2014
Published online: November 18, 2014
Core Tip

Core tip: Connective tissue growth factor (CTGF) plays an important role in the pathogenesis of rheumatoid arthritis (RA). We propose that CTGF is a potentially novel effector molecule in the pathogenesis of RA. Blocking the CTGF pathways by biological agents may have great beneficial effect in patients with RA.